| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.ATHEROSCLEROSIS.2013.04.031 |
| P698 | PubMed publication ID | 23746537 |
| P50 | author | Marc Kok | Q86916512 |
| Geesje M Dallinga-Thie | Q88427173 | ||
| Paul P Tak | Q89865007 | ||
| P2093 | author name string | Matthias Laudes | |
| Danielle M Gerlag | |||
| Uwe J F Tietge | |||
| Erik S G Stroes | |||
| Dominik M Schulte | |||
| Nike Müller | |||
| Radjesh J Bisoendial | |||
| Sander W Tas | |||
| Johannes H M Levels | |||
| Aart C Strang | |||
| Ruud S Kootte | |||
| Koen Vos | |||
| P433 | issue | 1 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| tocilizumab | Q425154 | ||
| atherosclerosis | Q12252367 | ||
| P304 | page(s) | 174-181 | |
| P577 | publication date | 2013-05-11 | |
| P1433 | published in | Atherosclerosis | Q4813570 |
| P1476 | title | Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis | |
| P478 | volume | 229 |
| Q36557611 | A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease |
| Q39051784 | Anti-inflammatory drugs as promising cardiovascular treatments. |
| Q64355353 | Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy: A Phenome-Wide Association Study |
| Q38737288 | Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk |
| Q28082992 | Cardiovascular disease risk scores in the current practice: which to use in rheumatoid arthritis? |
| Q92628084 | Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis |
| Q40959053 | Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis |
| Q38745362 | Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis |
| Q26770209 | From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection |
| Q35536380 | IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans |
| Q34025142 | IL-6 in diabetes and cardiovascular complications. |
| Q52312175 | Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. |
| Q88562718 | Interleukin-6: designing specific therapeutics for a complex cytokine |
| Q54966272 | Is interleukin-6 the link between low LDL cholesterol and increased non-cardiovascular mortality in the elderly? |
| Q38181566 | Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-α blockers: a meta-analysis of prospective studies |
| Q58567872 | Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment |
| Q34162072 | Modifications in lipid levels are independent of serum TNF-α in rheumatoid arthritis: results of an observational 24-week cohort study comparing patients receiving etanercept plus methotrexate or methotrexate as monotherapy |
| Q40675523 | Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy |
| Q50186670 | Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes. |
| Q49603124 | Potential of anti-inflammatory agents for treatment of atherosclerosis |
| Q38827889 | Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance |
| Q48145497 | Statin drug interactions and related adverse reactions: an update |
| Q38411334 | Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis |
| Q52574737 | Synergistic effect of interleukin-17 and tumor necrosis factor-α on inflammatory response in hepatocytes through interleukin-6 dependent and independent pathways. |
| Q97521704 | Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients |
| Q36234050 | Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. |
| Q36757435 | Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years |
| Q37682799 | Tocilizumab in the treatment of rheumatoid arthritis and beyond |
| Q39215606 | Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials |
| Q35118364 | What is the future of targeted therapy in rheumatology: biologics or small molecules? |
Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120 Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120
Search more.